Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein AS, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT.
DiNardo CD, et al. Among authors: patel pa.
Blood Adv. 2024 Apr 19:bloodadvances.2023012302. doi: 10.1182/bloodadvances.2023012302. Online ahead of print.
Blood Adv. 2024.
PMID: 38640348